title: Cardiovascular risk factors after liver transplantation: analysis of related factors.
abstract: OBJECTIVE
  We sought to analyze the cardiovascular risk factors (CVRF) in liver transplantation and their relation to immunosuppression and hepatitis C virus (HCV) infection.
  
  
  METHODS
  The study included all 158 liver transplants performed between January 2005 and December 2008 that had a minimum follow-up of 1 year. There were 104 men (64%) and 54 women (36%). Data were recorded on both the pretransplant prevalence as well as new cases of diabetes mellitus (DM), hypertension, hypertriglyceridemia, hypercholesterolemia, and hyperuricemia, defined by the need for drug therapy, after a mean follow-up period of 38 months (range, 12-64). We also examined the influence on CVRF of immunosuppression and HCV.
  
  
  RESULTS
  Tacrolimus was prescribed for 61% of the patients and cyclosporine, 39%. Upon univariate analysis only hypertension was significantly associated with the use of cyclosporine (P < .03). There was a trend to a greater incidence of hypercholesterolemia with cyclosporine (P = .1) and DM with tacrolimus (P = .1). The presence of HCV was significantly associated with a greater incidence of de novo DM (P < .01), as was a severe relapse of hepatitis C (P < .03). Multivariate analysis showed a 4.4 times greater risk for developing de novo DM among patients with a severe relapse of HCV.
  
  
  CONCLUSIONS
  The development of CVRF after liver transplantation was manifested, mainly during the first 3 months posttransplantation. Special attention should be given to the risk for de novo DM among HCV positive patients.
authors.affiliation: Unidad de Hepatología-Trasplante Hepático, Hospital Universitario Carlos Haya, Málaga, Spain. mjimenezp@commalaga.com
authors.forename: M J
authors.initials: MJ
authors.lastname: Pérez
authors.forename: D M
authors.initials: DM
authors.lastname: García
authors.forename: B J
authors.initials: BJ
authors.lastname: Taybi
authors.forename: J A P
authors.initials: JA
authors.lastname: Daga
authors.forename: J M L
authors.initials: JM
authors.lastname: Rey
authors.forename: R G
authors.initials: RG
authors.lastname: Grande
authors.forename: J D L C
authors.initials: JD
authors.lastname: Lombardo
authors.forename: J M R
authors.initials: JM
authors.lastname: López
mesh_terms: D002318:Cardiovascular Diseases / Q000453:epidemiology / Q000209:etiology*; D016572:Cyclosporine / Q000008:administration & dosage; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage; D016031:Liver Transplantation / Q000009:adverse effects*; D008297:Male; D015999:Multivariate Analysis; D015995:Prevalence; D012307:Risk Factors; D016559:Tacrolimus / Q000008:administration & dosage
chemical_list: D007166:Immunosuppressive Agents; D016572:Cyclosporine; D016559:Tacrolimus